FFA
CRBU icon

Frazier Financial Advisors’s Caribou Biosciences CRBU Stock Holding History

Frazier Financial Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40
Closed -$37 – 626
2025
Q1 		$37 Hold
40
– – ﹤0.01% 590
2024
Q4 		$65 Hold
40
– – ﹤0.01% 626
2024
Q3 		$79 Hold
40
– – ﹤0.01% 816
2024
Q2 		$66 Hold
40
– – ﹤0.01% 955
2024
Q1 		$206 Buy
+40
New +$247 ﹤0.01% 865

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Frazier Financial Advisors's CRBU Position: Q2 2025 in Review

Frazier Financial Advisors sold out of Caribou Biosciences (CRBU) in Q2 2025, closing a stake of 40 shares — an estimated $37 sold.

Frazier Financial Advisors first reported a position in CRBU in Q1 2024 and held it in 5 quarters. The position peaked at $206 in Q1 2024. 129 funds tracked by Wall St. Rank hold CRBU as of Q2 2025.

  • Frazier Financial Advisors reported no remaining Caribou Biosciences position as of Q2 2025 after selling out during the quarter.
  • Frazier Financial Advisors sold 40 Caribou Biosciences shares in Q2 2025, an estimated $37.
  • Frazier Financial Advisors first reported a position in Caribou Biosciences in Q1 2024 and held it in 5 quarters.
  • Frazier Financial Advisors's Caribou Biosciences position peaked at $206 in Q1 2024.
  • 129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2025.

Based on Frazier Financial Advisors's 13F filing for Q2 2025, filed 28 Jul 2025.